Eric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt purchased 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The stock was bought at an average cost of $24.80 per share, with a total value of $49,600.00. Following the completion of the transaction, the chief financial officer now owns 14,000 shares of the company’s stock, valued at $347,200. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 18th, Eric Bjerkholt acquired 2,000 shares of Mirum Pharmaceuticals stock. The stock was purchased at an average price of $25.80 per share, for a total transaction of $51,600.00.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $25.12 on Thursday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The company has a market cap of $1.18 billion, a P/E ratio of -6.33 and a beta of 1.16. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $21.83 and a fifty-two week high of $35.56. The business’s 50 day moving average price is $27.49 and its 200-day moving average price is $29.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.32). The firm had revenue of $69.55 million during the quarter, compared to analysts’ expectations of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Eventide Asset Management LLC increased its stake in Mirum Pharmaceuticals by 68.0% in the 2nd quarter. Eventide Asset Management LLC now owns 3,459,201 shares of the company’s stock worth $89,490,000 after purchasing an additional 1,400,000 shares in the last quarter. Avidity Partners Management LP acquired a new position in Mirum Pharmaceuticals in the third quarter worth $36,114,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Mirum Pharmaceuticals by 3,544.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,164,682 shares of the company’s stock valued at $34,383,000 after acquiring an additional 1,132,723 shares during the period. Polar Capital Holdings Plc bought a new stake in Mirum Pharmaceuticals in the first quarter valued at about $21,441,000. Finally, First Turn Management LLC bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth about $24,688,000.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. JMP Securities boosted their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. HC Wainwright raised their target price on Mirum Pharmaceuticals from $45.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. SVB Leerink reduced their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Finally, Raymond James lowered their price objective on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a research report on Tuesday, December 19th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $52.11.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.